U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Hypopigmentation of hair

MedGen UID:
480031
Concept ID:
C3278401
Finding
Synonym: Hair hypopigmentation
 
HPO: HP:0005599

Conditions with this feature

Chédiak-Higashi syndrome
MedGen UID:
3347
Concept ID:
C0007965
Disease or Syndrome
Chediak-Higashi syndrome (CHS) is characterized by partial oculocutaneous albinism, immunodeficiency, and a mild bleeding tendency. Approximately 85% of affected individuals develop the accelerated phase, or hemophagocytic lymphohistiocytosis, a life-threatening, hyperinflammatory condition. All affected individuals including adolescents and adults with atypical CHS and children with classic CHS who have successfully undergone allogenic hematopoietic stem cell transplantation (HSCT) develop neurologic findings during early adulthood.
Tyrosinase-positive oculocutaneous albinism
MedGen UID:
82810
Concept ID:
C0268495
Disease or Syndrome
Tyrosinase-positive oculocutaneous albinism (OCA, type II; OCA2) is an autosomal recessive disorder in which the biosynthesis of melanin pigment is reduced in skin, hair, and eyes. Although affected infants may appear at birth to have OCA type I, or complete absence of melanin pigment, most patients with OCA type II acquire small amounts of pigment with age. Individuals with OCA type II have the characteristic visual anomalies associated with albinism, including decreased acuity and nystagmus, which are usually less severe than in OCA type I (Lee et al., 1994; King et al., 2001). OCA type II has a highly variable phenotype. The hair of affected individuals may turn darker with age, and pigmented nevi or freckles may be seen. African and African American individuals may have yellow hair and blue-gray or hazel irides. One phenotypic variant, 'brown OCA,' has been described in African and African American populations and is characterized by light brown hair and skin color and gray to tan irides. The hair and irides may turn darker with time and the skin may tan with sun exposure; the ocular features of albinism are present in all variants (King et al., 2001). In addition, previous reports of so-called 'autosomal recessive ocular albinism,' (see, e.g., Witkop et al., 1978 and O'Donnell et al., 1978) with little or no obvious skin involvement, are now considered most likely to be part of the phenotypic spectrum of OCA1 or OCA2 (Lee et al., 1994; King et al., 2001).
Oculocutaneous albinism type 1B
MedGen UID:
337712
Concept ID:
C1847024
Disease or Syndrome
Oculocutaneous albinism type I is an autosomal recessive disorder characterized by absence of pigment in hair, skin, and eyes, and does not vary with race or age. Severe nystagmus, photophobia, and reduced visual acuity are common features. OCA type I is divided into 2 types: type IA, characterized by complete lack of tyrosinase activity due to production of an inactive enzyme, and type IB, characterized by reduced activity of tyrosinase. Although OCA caused by mutations in the TYR gene was classically known as 'tyrosinase-negative' OCA, Tripathi et al. (1992) noted that some patients with 'tyrosinase-positive' OCA may indeed have TYR mutations resulting in residual enzyme activity. These patients can be classified as having OCA1B.
Oculocutaneous albinism type 4
MedGen UID:
338324
Concept ID:
C1847836
Disease or Syndrome
Oculocutaneous albinism type 4 (OCA4) is characterized by hypopigmentation of the hair and skin plus the characteristic ocular changes found in all other types of albinism, including: nystagmus; reduced iris pigment with iris translucency; reduced retinal pigment with visualization of the choroidal blood vessels on ophthalmoscopic examination; foveal hypoplasia associated with reduction in visual acuity; and misrouting of the optic nerves at the chiasm associated with alternating strabismus, reduced stereoscopic vision, and an altered visual evoked potential (VEP). Individuals with OCA4 are usually recognized within the first year of life because of hypopigmentation of the hair and skin and the ocular features of nystagmus and strabismus. Vision is likely to be stable after early childhood. The amount of cutaneous pigmentation in OCA4 ranges from minimal to near normal. Newborns with OCA4 usually have some pigment in their hair, with color ranging from silvery white to light yellow. Hair color may darken with time, but does not vary significantly from childhood to adulthood.
Vici syndrome
MedGen UID:
340962
Concept ID:
C1855772
Disease or Syndrome
With the current widespread use of multigene panels and comprehensive genomic testing, it has become apparent that the phenotypic spectrum of EPG5-related disorder represents a continuum. At the most severe end of the spectrum is classic Vici syndrome (defined as a neurodevelopmental disorder with multisystem involvement characterized by the combination of agenesis of the corpus callosum, cataracts, hypopigmentation, cardiomyopathy, combined immunodeficiency, microcephaly, and failure to thrive); at the milder end of the spectrum are attenuated neurodevelopmental phenotypes with variable multisystem involvement. Median survival in classic Vici syndrome appears to be 24 months, with only 10% of children surviving longer than age five years; the most common causes of death are respiratory infections as a result of primary immunodeficiency and/or cardiac insufficiency resulting from progressive cardiac failure. No data are available on life span in individuals at the milder end of the spectrum.
Nephropathic cystinosis
MedGen UID:
419735
Concept ID:
C2931187
Disease or Syndrome
Cystinosis comprises three allelic phenotypes: Nephropathic cystinosis in untreated children is characterized by renal Fanconi syndrome, poor growth, hypophosphatemic/calcipenic rickets, impaired glomerular function resulting in complete glomerular failure, and accumulation of cystine in almost all cells, leading to cellular dysfunction with tissue and organ impairment. The typical untreated child has short stature, rickets, and photophobia. Failure to thrive is generally noticed after approximately age six months; signs of renal tubular Fanconi syndrome (polyuria, polydipsia, dehydration, and acidosis) appear as early as age six months; corneal crystals can be present before age one year and are always present after age 16 months. Prior to the use of renal transplantation and cystine-depleting therapy, the life span in nephropathic cystinosis was no longer than ten years. With these interventions, affected individuals can survive at least into the mid-forties or fifties with satisfactory quality of life. Intermediate cystinosis is characterized by all the typical manifestations of nephropathic cystinosis, but onset is at a later age. Renal glomerular failure occurs in all untreated affected individuals, usually between ages 15 and 25 years. The non-nephropathic (ocular) form of cystinosis is characterized clinically only by photophobia resulting from corneal cystine crystal accumulation.
Hermansky-Pudlak syndrome 1
MedGen UID:
419514
Concept ID:
C2931875
Disease or Syndrome
Hermansky-Pudlak syndrome (HPS) is characterized by oculocutaneous albinism, a bleeding diathesis, and, in some individuals, pulmonary fibrosis, granulomatous colitis, or immunodeficiency. Ocular findings include reduced iris pigment with iris transillumination, reduced retinal pigment, foveal hypoplasia with significant reduction in visual acuity (usually in the range of 20/50 to 20/400), nystagmus, and increased crossing of the optic nerve fibers. Hair color ranges from white to brown; skin color ranges from white to olive and is usually a shade lighter than that of other family members. The bleeding diathesis can result in variable bruising, epistaxis, gingival bleeding, postpartum hemorrhage, colonic bleeding, and prolonged bleeding with menses or after tooth extraction, circumcision, and other surgeries. Pulmonary fibrosis, a restrictive lung disease, typically causes symptoms in the early thirties and can progress to death within a decade. Granulomatous colitis is severe in about 15% of affected individuals. Neutropenia and/or immune defects occur primarily in individuals with pathogenic variants in AP3B1 and AP3D1.
Hermansky-Pudlak syndrome 3
MedGen UID:
854708
Concept ID:
C3888001
Disease or Syndrome
Hermansky-Pudlak syndrome (HPS) is characterized by oculocutaneous albinism, a bleeding diathesis, and, in some individuals, pulmonary fibrosis, granulomatous colitis, or immunodeficiency. Ocular findings include reduced iris pigment with iris transillumination, reduced retinal pigment, foveal hypoplasia with significant reduction in visual acuity (usually in the range of 20/50 to 20/400), nystagmus, and increased crossing of the optic nerve fibers. Hair color ranges from white to brown; skin color ranges from white to olive and is usually a shade lighter than that of other family members. The bleeding diathesis can result in variable bruising, epistaxis, gingival bleeding, postpartum hemorrhage, colonic bleeding, and prolonged bleeding with menses or after tooth extraction, circumcision, and other surgeries. Pulmonary fibrosis, a restrictive lung disease, typically causes symptoms in the early thirties and can progress to death within a decade. Granulomatous colitis is severe in about 15% of affected individuals. Neutropenia and/or immune defects occur primarily in individuals with pathogenic variants in AP3B1 and AP3D1.
Tyrosinase-negative oculocutaneous albinism
MedGen UID:
1643910
Concept ID:
C4551504
Disease or Syndrome
Researchers have identified multiple types of oculocutaneous albinism, which are distinguished by their specific skin, hair, and eye color changes and by their genetic cause. Oculocutaneous albinism type 1 is characterized by white hair, very pale skin, and light-colored irises. Type 2 is typically less severe than type 1; the skin is usually a creamy white color and hair may be light yellow, blond, or light brown. Type 3 includes a form of albinism called rufous oculocutaneous albinism, which usually affects dark-skinned people. Affected individuals have reddish-brown skin, ginger or red hair, and hazel or brown irises. Type 3 is often associated with milder vision abnormalities than the other forms of oculocutaneous albinism. Type 4 has signs and symptoms similar to those seen with type 2.\n\nOculocutaneous albinism is a group of conditions that affect coloring (pigmentation) of the skin, hair, and eyes. Affected individuals typically have very fair skin and white or light-colored hair. Long-term sun exposure greatly increases the risk of skin damage and skin cancers, including an aggressive form of skin cancer called melanoma, in people with this condition. Oculocutaneous albinism also reduces pigmentation of the colored part of the eye (the iris) and the light-sensitive tissue at the back of the eye (the retina). People with this condition usually have vision problems such as reduced sharpness; rapid, involuntary eye movements (nystagmus); and increased sensitivity to light (photophobia).\n\nSeveral additional types of this disorder have been proposed, each affecting one or a few families.
Hypopigmentation, organomegaly, and delayed myelination and development
MedGen UID:
1684826
Concept ID:
C5203300
Disease or Syndrome
Hypopigmentation, organomegaly, and delayed myelination and development (HOD) is characterized by hypopigmented skin and hair with normally pigmented irides; organomegaly including enlargement of liver, kidney, and spleen; and delayed myelination on brain MRI accompanied by developmental delay in both gross and fine motor skills. Biopsy findings from skin and other organs are consistent with a lysosomal storage disorder (Nicoli et al., 2019).
Oculocutaneous albinism type 8
MedGen UID:
1754121
Concept ID:
C5436929
Disease or Syndrome
Oculocutaneous albinism type VIII (OCA8) is characterized by mild hair and skin hypopigmentation, associated with ocular features including nystagmus, reduced visual acuity, iris transillumination, and hypopigmentation of the retina (Pennamen et al., 2021).
DEGCAGS syndrome
MedGen UID:
1794177
Concept ID:
C5561967
Disease or Syndrome
DEGCAGS syndrome is an autosomal recessive syndromic neurodevelopmental disorder characterized by global developmental delay, coarse and dysmorphic facial features, and poor growth and feeding apparent from infancy. Affected individuals have variable systemic manifestations often with significant structural defects of the cardiovascular, genitourinary, gastrointestinal, and/or skeletal systems. Additional features may include sensorineural hearing loss, hypotonia, anemia or pancytopenia, and immunodeficiency with recurrent infections. Death in childhood may occur (summary by Bertoli-Avella et al., 2021).

Professional guidelines

PubMed

Kawakami T
J Dermatol 2022 Apr;49(4):391-401. Epub 2022 Feb 17 doi: 10.1111/1346-8138.16316. PMID: 35178747
Rossi AM, Hibler BP, Navarrete-Dechent C, Lacouture ME
J Am Acad Dermatol 2021 Sep;85(3):693-707. Epub 2020 Aug 8 doi: 10.1016/j.jaad.2020.08.005. PMID: 32781177Free PMC Article
Ghasemi M, Bajouri A, Shafiiyan S, Aghdami N
Tissue Eng Regen Med 2020 Dec;17(6):815-827. Epub 2020 Oct 9 doi: 10.1007/s13770-020-00284-2. PMID: 33034877Free PMC Article

Recent clinical studies

Etiology

Dauendorffer JN, Skayem C, Passeron T
Ann Dermatol Venereol 2022 Jun;149(2):92-98. Epub 2021 Jul 2 doi: 10.1016/j.annder.2021.06.003. PMID: 34226034
Yardman-Frank JM, Fisher DE
Exp Dermatol 2021 Apr;30(4):560-571. Epub 2020 Dec 24 doi: 10.1111/exd.14260. PMID: 33320376Free PMC Article
Zhong Z, Gu L, Zheng X, Ma N, Wu Z, Duan J, Zhang J, Chen J
Pigment Cell Melanoma Res 2019 Sep;32(5):672-686. Epub 2019 May 29 doi: 10.1111/pcmr.12790. PMID: 31077556Free PMC Article
Kostovski M, Tasic V, Laban N, Polenakovic M, Danilovski D, Gucev Z
Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2017 Dec 1;38(3):121-133. doi: 10.2478/prilozi-2018-0013. PMID: 29668472
Grønskov K, Ek J, Brondum-Nielsen K
Orphanet J Rare Dis 2007 Nov 2;2:43. doi: 10.1186/1750-1172-2-43. PMID: 17980020Free PMC Article

Diagnosis

Elhawary NA, AlJahdali IA, Abumansour IS, Elhawary EN, Gaboon N, Dandini M, Madkhali A, Alosaimi W, Alzahrani A, Aljohani F, Melibary EM, Kensara OA
Hum Genomics 2022 Jul 19;16(1):22. doi: 10.1186/s40246-022-00398-9. PMID: 35854334Free PMC Article
Ezzedine K, Eleftheriadou V, Whitton M, van Geel N
Lancet 2015 Jul 4;386(9988):74-84. Epub 2015 Jan 15 doi: 10.1016/S0140-6736(14)60763-7. PMID: 25596811
Simeonov DR, Wang X, Wang C, Sergeev Y, Dolinska M, Bower M, Fischer R, Winer D, Dubrovsky G, Balog JZ, Huizing M, Hart R, Zein WM, Gahl WA, Brooks BP, Adams DR
Hum Mutat 2013 Jun;34(6):827-35. Epub 2013 Apr 30 doi: 10.1002/humu.22315. PMID: 23504663Free PMC Article
Oiso N, Fukai K, Kawada A, Suzuki T
J Dermatol 2013 May;40(5):330-5. Epub 2012 Jun 1 doi: 10.1111/j.1346-8138.2012.01583.x. PMID: 22670867
Grønskov K, Ek J, Brondum-Nielsen K
Orphanet J Rare Dis 2007 Nov 2;2:43. doi: 10.1186/1750-1172-2-43. PMID: 17980020Free PMC Article

Therapy

Elhawary NA, AlJahdali IA, Abumansour IS, Elhawary EN, Gaboon N, Dandini M, Madkhali A, Alosaimi W, Alzahrani A, Aljohani F, Melibary EM, Kensara OA
Hum Genomics 2022 Jul 19;16(1):22. doi: 10.1186/s40246-022-00398-9. PMID: 35854334Free PMC Article
Freites-Martinez A, Shapiro J, Goldfarb S, Nangia J, Jimenez JJ, Paus R, Lacouture ME
J Am Acad Dermatol 2019 May;80(5):1179-1196. Epub 2018 Apr 14 doi: 10.1016/j.jaad.2018.03.055. PMID: 29660422Free PMC Article
Harris JE
Dermatol Clin 2017 Apr;35(2):151-161. doi: 10.1016/j.det.2016.11.006. PMID: 28317525Free PMC Article
Ezzedine K, Eleftheriadou V, Whitton M, van Geel N
Lancet 2015 Jul 4;386(9988):74-84. Epub 2015 Jan 15 doi: 10.1016/S0140-6736(14)60763-7. PMID: 25596811
Riley PA
Int J Biochem Cell Biol 1997 Nov;29(11):1235-9. doi: 10.1016/s1357-2725(97)00013-7. PMID: 9451820

Prognosis

Roberts GHL, Santorico SA, Spritz RA
Pigment Cell Melanoma Res 2020 Jan;33(1):8-15. Epub 2019 Dec 4 doi: 10.1111/pcmr.12848. PMID: 31743585Free PMC Article
Kostovski M, Tasic V, Laban N, Polenakovic M, Danilovski D, Gucev Z
Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2017 Dec 1;38(3):121-133. doi: 10.2478/prilozi-2018-0013. PMID: 29668472
Ezzedine K, Eleftheriadou V, Whitton M, van Geel N
Lancet 2015 Jul 4;386(9988):74-84. Epub 2015 Jan 15 doi: 10.1016/S0140-6736(14)60763-7. PMID: 25596811
Simeonov DR, Wang X, Wang C, Sergeev Y, Dolinska M, Bower M, Fischer R, Winer D, Dubrovsky G, Balog JZ, Huizing M, Hart R, Zein WM, Gahl WA, Brooks BP, Adams DR
Hum Mutat 2013 Jun;34(6):827-35. Epub 2013 Apr 30 doi: 10.1002/humu.22315. PMID: 23504663Free PMC Article
Kakourou T
World J Pediatr 2009 Nov;5(4):265-8. Epub 2009 Nov 13 doi: 10.1007/s12519-009-0050-1. PMID: 19911140

Clinical prediction guides

Kussainova A, Kassym L, Bekenova N, Akhmetova A, Glushkova N, Kussainov A, Urazalina Z, Yurkovskaya O, Smail Y, Pak L, Semenova Y
PLoS One 2022;17(7):e0271719. Epub 2022 Jul 29 doi: 10.1371/journal.pone.0271719. PMID: 35905107Free PMC Article
Roberts GHL, Santorico SA, Spritz RA
Pigment Cell Melanoma Res 2020 Jan;33(1):8-15. Epub 2019 Dec 4 doi: 10.1111/pcmr.12848. PMID: 31743585Free PMC Article
Ainger SA, Jagirdar K, Lee KJ, Soyer HP, Sturm RA
Dermatology 2017;233(1):1-15. Epub 2017 May 3 doi: 10.1159/000468538. PMID: 28463841
Simeonov DR, Wang X, Wang C, Sergeev Y, Dolinska M, Bower M, Fischer R, Winer D, Dubrovsky G, Balog JZ, Huizing M, Hart R, Zein WM, Gahl WA, Brooks BP, Adams DR
Hum Mutat 2013 Jun;34(6):827-35. Epub 2013 Apr 30 doi: 10.1002/humu.22315. PMID: 23504663Free PMC Article
Le Poole C, Boissy RE
Semin Cutan Med Surg 1997 Mar;16(1):3-14. doi: 10.1016/s1085-5629(97)80030-2. PMID: 9125760

Recent systematic reviews

Gregoric N, Groselj U, Bratina N, Debeljak M, Zerjav Tansek M, Suput Omladic J, Kovac J, Battelino T, Kotnik P, Avbelj Stefanija M
Front Endocrinol (Lausanne) 2021;12:689387. Epub 2021 Jun 9 doi: 10.3389/fendo.2021.689387. PMID: 34177811Free PMC Article
Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME
J Am Acad Dermatol 2017 Nov;77(5):902-910.e2. Epub 2017 Sep 14 doi: 10.1016/j.jaad.2017.06.044. PMID: 28918974Free PMC Article
Rusfianti M, Wirohadidjodjo YW
Int J Dermatol 2006 Apr;45(4):411-7. doi: 10.1111/j.1365-4632.2006.02486.x. PMID: 16650168

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...